Biosimilar medicine authorized by the European Commission
ACTIVE PRINCIPLE:
Trastuzumab
INDICATION:
Breast cancer
Stomach cancer
DATE:
15/11/2023
STATUS:
Authorized
Subscribe to receive a weekly summary of current events on biosimilar medicines in your email.